about
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomyEvolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancerPatient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancerGenomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers.RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.Transcriptome-wide detection of differentially expressed coding and non-coding transcripts and their clinical significance in prostate cancer.Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapiesGermline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate CancerThe long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1.Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies.Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer.Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality.The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes.Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report.Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer.Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome.Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy SpecimensRacial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor LocationTissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.Whole-transcriptome profiling of thyroid nodules identifies expression-based signatures for accurate thyroid cancer diagnosis.AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures.TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.
P50
Q28534277-330B2AB9-8414-4354-99B9-FBD62C5D7917Q30938412-626E43C1-72BC-4872-958C-F76F377B7067Q33793232-EC7B89F9-C210-46D8-907B-E47E50483336Q33898869-D78BBE87-4250-4B37-B613-CCC162691C7CQ34550412-94DBB082-88BB-419A-ACDE-CB1C001AD60AQ34563208-A04AFE93-1E02-414A-8CA9-B3862DF086FDQ35771477-5791A441-904E-47BF-BA99-0FF357376A48Q36025180-F551B7FE-0435-40F0-BD51-41A17841B662Q36035812-1F05B2FC-3C42-4FC9-9F37-3064BF2ED851Q36172537-4FAE5079-32FD-401A-87E8-A983ED45311FQ36200124-D222173D-26B3-4EDE-AD03-362179B2FABEQ36236135-75177700-4634-4BF3-9CE0-7F397585409DQ36356386-80F05209-564A-4CD6-8D0C-520CF45033D7Q36471474-0EC57F74-DB1B-479D-91E0-9352430B21DDQ37266000-4E553BA1-F694-4293-8685-0B72A0A23A5FQ37269294-44CCCB7E-CFF3-4A15-848F-D82BF8C4C2DEQ37619763-D09D6B26-2984-45FA-B444-F0EFB0FFFD76Q38431287-9F49283F-A97A-4674-8D5A-732E597DAC07Q38615085-1B852635-B799-430C-A5EF-8209840EE3AFQ38655046-98A5954F-1417-48FF-A3D5-47BF7A330B52Q38673660-4A88395D-8129-4916-87B3-BB79BC482BBCQ38767990-1FD42669-9CBB-4617-B716-5C683397B137Q38814732-BAD52D8B-4080-429F-923B-C1EFB9554525Q38841717-89D223B0-0C4F-4673-B0BF-5A06C80C23DCQ38938642-7F719F57-D1E0-4E0B-952B-2E735C360896Q38989776-D00978BE-4FD0-4470-A463-77188489F3AEQ39288342-2FEBC82B-AB84-4001-8057-94E548971486Q39314574-65DF8061-C9AF-48D5-8493-E2C3624F0E9CQ39558077-42537CBC-FBA4-4982-85A9-F05E0BBF5846Q39683347-FFE5C276-C0D2-436A-978C-F0835481A2BBQ39946238-3C443267-2B93-43D9-B354-501F66AC8506Q40006369-DD15F99A-F760-48FF-959C-724F4727EF27Q40853088-C959FA72-755B-4451-83AF-66D9CE5BADA1Q41612462-2A1C67E4-1C29-4B2D-BD80-84BC94903E04Q42508303-7CF5846F-8941-4296-8D33-FB94E65E497AQ42509592-0285840D-FD3C-433F-B7D2-BA52A16B8A1BQ43469239-183479C3-06BC-4DE0-971B-3567C2FAE2CCQ43869209-CBD2F651-EFDD-4EC6-BA72-9399426E6576Q46001301-E177E9FC-97D2-4167-A9DF-C70518A8FC3FQ46838481-8C06B57C-0E8D-4E86-B05D-316142A22CD2
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicholas Erho
@ast
Nicholas Erho
@en
Nicholas Erho
@es
Nicholas Erho
@nl
Nicholas Erho
@sl
type
label
Nicholas Erho
@ast
Nicholas Erho
@en
Nicholas Erho
@es
Nicholas Erho
@nl
Nicholas Erho
@sl
prefLabel
Nicholas Erho
@ast
Nicholas Erho
@en
Nicholas Erho
@es
Nicholas Erho
@nl
Nicholas Erho
@sl
P106
P21
P31
P496
0000-0002-5857-2701